What is DNAnexus?
Headquartered in Mountain View, California, DNAnexus operates as a leading bioinformatics platform provider. The company specializes in creating secure, end-to-end integrated environments that support both diagnostic R&D and large-scale production bioinformatics. By bridging the gap between complex genomic information and actionable clinical insights, DNAnexus empowers internal and external teams to collaborate effectively. Its market position is defined by its ability to handle massive datasets, supporting population genomics projects and multi-omics research that are essential for modern drug discovery and personalized healthcare delivery.
How much funding has DNAnexus raised?
DNAnexus has raised a total of $472.6M across 8 funding rounds:
Series B
$15M
Series C
$15M
Series D
$15M
Series E
$58M
Series F
$68M
Series G
$100M
Unspecified
$200M
Series B (2011): $15M led by First Round Capital, SoftTech VC, K9 Ventures, Google Ventures, TPG Biotech, and Felicis Ventures
Series C (2013): $15M supported by First Round Capital, Google Ventures, Claremont Creek Ventures, and TPG Biotech
Series D (2015): $15M featuring WuXi AppTec
Series E (2018): $58M backed by Claremont Creek Ventures, MidCap Financial, WuXi NextCODE, Foresite Capital, Google Ventures, TPG Biotech, and Microsoft
Series F (2019): $68M with participation from GV, TPG Biotech, Foresite Capital, Claremont Creek Ventures, Innovatus Capital Partners, and WuXi NextCODE
Series G (2020): $100M led by Regeneron Pharmaceuticals , Inc., Perceptive Advisors LLC, Foresite Capital, First Round Capital, Texas Pacific Group, Google Ventures, and Northpond Ventures LLC
Unspecified (2022): $200M supported by Foresite Capital, Blackstone Accelerates Growth, Innovatus Capital Partners, Northpond Ventures, Perceptive Advisors, and GV
Key Investors in DNAnexus
GV
A venture capital firm founded in 2001 that invests across multiple stages and sectors, focusing on enterprise solutions, life sciences, and frontier technology innovations.
TPG Biotech
A global alternative asset management firm with deep expertise in growth equity and life sciences, partnering with businesses to drive long-term value creation.
Foresite Capital
A multi-stage investment firm that utilizes a data science-driven approach to transform healthcare and life sciences by funding visionary companies at the intersection of biology and big data.
What's next for DNAnexus?
Looking ahead, the strategic deployment of $200M is expected to accelerate the company's expansion into new therapeutic areas and enhance its cloud-based data science capabilities. As the demand for high-throughput genomic analysis continues to surge, DNAnexus is well-positioned to scale its infrastructure to meet the needs of global pharmaceutical partners and national health initiatives. The company's focus remains on refining its platform to ensure seamless integration of multi-omics data, thereby maintaining its competitive edge in the rapidly evolving landscape of digital health and biotechnology.
See full DNAnexus company page
